IL6 and neoplasm: The anti-tumor drug 3,3’-diindolylmethane (DIM) activates NF-κB signaling in gastric cancer-TA-MSCs, enhancing their secretion of IL-6, IL-8 and CCL2, which in turn promotes cancer cell proliferation [231].